Drug intelligence / Profile preview

TRX-611

Development stage: Preclinical
Lead developer: TRX Biosciences
Modality: Small Molecules
Administration: Oral

Overview

TRX-611 is an investigational drug candidate being developed by TRX Biosciences for the treatment of inflammatory bowel disease (IBD). The drug utilizes TRX Biosciences' proprietary LipiCore™ technology, a lipid-based delivery platform designed to enhance the oral bioavailability and enable the targeted delivery of molecules to specific organs, cells, and tissues. TRX-611 is intended to modulate the anti-inflammatory response within the gastrointestinal tract. While it is a key part of the company's wholly-owned pipeline, specific details regarding its molecular target, chemical structure, and current clinical development phase have not been publicly disclosed.

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)

Beyond the preview

Go deeper on TRX-611.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRX-611.

Explore the full profile